Alpha hydroxy acids
This article was originally published in The Tan Sheet
FDA is still "grappling" with the issue of whether and how to regulate alpha hydroxy acid skin care products, John Bailey, director of the Office of Cosmetics and Colors, told FDA's Dermatologic Drugs Advisory Committee Sept. 22 ("The Tan Sheet" Jan. 3, p. 24). "It will be a very challenging process for FDA to define the difference between the drug uses of AHA and cosmetics uses in broad terms such as a policy statement," he added. However, Bailey noted one distinction: "If, under certain conditions with the formulation, only superficial exfoliation is occurring, then these are cosmetics and we would have no problem with them," he said. On the other hand, "if there's significant loss of stratum corneum and the physiological process of skin is impaired, then I think we're...looking at drugs"
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC